Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL28726469 | 0.97 | SIGMAR1 (0.62) | SIGMAR1ALDH1A1KCNH2NOTUMCHRM2 | |
| Oxalic Acid SCHEMBL1894518 | 0.97 | SIGMAR1 (0.62) | SIGMAR1ALDH1A1KCNH2NOTUMCHRM2 | |
| SCHEMBL5185066 | 0.90 | SIGMAR1 (0.72) | SIGMAR1KCNH2 | |
| SCHEMBL467214 | 0.84 | SIGMAR1 (0.67) | SIGMAR1KCNH2KDM4E | |
| Hydrochloric Acid SCHEMBL1896086 | 0.83 | SIGMAR1 (0.66) | SIGMAR1KCNH2KDM4E | |
| SCHEMBL467254 | 0.81 | SIGMAR1 (0.84) | SIGMAR1KCNH2 | |
| SCHEMBL467255 | 0.81 | SIGMAR1 (0.82) | SIGMAR1KCNH2 | |
| Oxalic Acid SCHEMBL19691744 | 0.79 | SIGMAR1 (0.79) | SIGMAR1KCNH2KDM4E | |
| SCHEMBL467402 | 0.79 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| Oxalic Acid SCHEMBL1897462 | 0.79 | SIGMAR1 (0.79) | SIGMAR1KCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010128-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2019-01-10 | — | — | US | claimed |
| EP-2600863-B1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | ESTEVE LABOR DR (ES) | 2018-03-28 | — | — | EP | claimed |
| US-20160310501-A1 | GABAPENTINOIDS AND SIGMA RECEPTOR LIGANDS COMBINATIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-10-27 | — | — | US | claimed |
| US-20160310500-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-10-27 | — | — | US | claimed |
| EP-3082782-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-10-26 | — | — | EP | claimed |
| EP-3082790-A1 | GABAPENTINOIDS AND SIGMA RECEPTOR LIGANDS COMBINATIONS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-10-26 | — | — | EP | claimed |
| US-20160220574-A1 | NSAID AND SIGMA RECEPTOR LIGAND COMBINATIONS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-08-04 | — | — | US | claimed |
| EP-3043795-A1 | NSAID AND SIGMA RECEPTOR LIGAND COMBINATIONS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-07-20 | — | — | EP | claimed |
| US-20160151377-A1 | USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS) | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-06-02 | — | — | US | claimed |
| EP-3013338-A1 | USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS) | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-05-04 | — | — | EP | claimed |
| WO-2011144721-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-24 | — | — | WO | claimed |
| EP-2388005-A1 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-11-23 | — | — | EP | claimed |
| WO-2011095585-A1 | SIGMA LIGANDS FOR POTENTIATING THE ANALGESIC EFFECT OF OPIOIDS AND OPIATES IN POST-OPERATIVE PAIN AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-11 | — | — | WO | claimed |
| EP-2353591-A1 | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-08-10 | — | — | EP | claimed |
| US-20110112095-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-12 | — | — | US | claimed |
| EP-2276744-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-01-26 | — | — | EP | claimed |
| US-20100190780-A1 | SIGMA RECEPTOR INHIBITORS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2010-07-29 | — | — | US | claimed |
| EP-2116539-A1 | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| WO-2009130310-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-29 | — | — | WO | claimed |
| US-20080125416-A1 | Sigma Receptor Inhibitors | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2008-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310500-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | SIGMAR1, OPRL1, SLC6A2 | SIGMAR1 1/4885ALDH1A1 490/4885KCNH2 1889/4885 |
| US-20160151377-A1 | USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS) | OPRL1, NPSR1, SIGMAR1 | SIGMAR1 3/4885ALDH1A1 1598/4885KCNH2 916/4885 |
| US-20160310501-A1 | GABAPENTINOIDS AND SIGMA RECEPTOR LIGANDS COMBINATIONS | SIGMAR1, OPRL1, OPRM1 | SIGMAR1 1/4885ALDH1A1 688/4885KCNH2 2068/4885 |
| US-20080125416-A1 | Sigma Receptor Inhibitors | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885ALDH1A1 777/4885KCNH2 1365/4885 |
| US-20190010128-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | OPRK1, OPRD1, SIGMAR1 | SIGMAR1 3/4885ALDH1A1 407/4885KCNH2 1308/4885 |
| US-20110112095-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | OPRK1, OPRD1, SIGMAR1 | SIGMAR1 3/4885ALDH1A1 407/4885KCNH2 1308/4885 |
| US-20160220574-A1 | NSAID AND SIGMA RECEPTOR LIGAND COMBINATIONS | SIGMAR1, OPRL1, OPRK1 | SIGMAR1 1/4885ALDH1A1 531/4885KCNH2 3492/4885 |
| US-20100190780-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885ALDH1A1 777/4885KCNH2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.